AI Clinical Trial Protocol Risk Assessment Playbook

A biotech's Phase 3 trial for a cardiovascular drug is 6 months from enrollment completion. An interim safety review flagged an unexpected adverse event rate of 3.2% in the treatment arm vs. 1.4% in placebo. The DSMB has not recommended trial discontinuation but the regulatory team wants an independent assessment.

When to use this playbook

• Use this playbook when the decision looks like the situation above: A biotech's Phase 3 trial for a cardiovascular drug is 6 months from enrollment completion.
• It is a fit when you have source files in hand and need a structured, reviewable analysis — not a generic chat answer about "Clinical Trial Protocol Risk Assessment".
• Do not use it as a substitute for licensed, legal, clinical, or authorized official judgment in the domain.

What you'll need

• Interim safety data report (treatment vs. placebo adverse event rates)
• Trial protocol and SAP (statistical analysis plan)
• DSMB meeting minutes and recommendation
• Comparable drug safety profiles from approved cardiovascular drugs
• FDA guidance on cardiovascular safety in drug trials

Attachments: Documents (Documents)

You are a clinical development regulatory specialist assessing Phase 3 trial safety signals for a cardiovascular drug. I am attaching:

Work only from the attached source files. If a conclusion is not supported, say so.

Produce:
1. Assess the clinical significance of the 3.2% vs. 1.4% adverse event rate: is this a drug-related effect, a chance finding, or an imbalance in baseline characteristics?
2. Review the adverse event types: are they class-related effects expected for this mechanism of action, or are they unexpected and potentially serious?
3. Assess the DSMB's decision to continue: is the benefit-risk balance supportable for the trial to continue to completion given the current signal?
4. Identify the regulatory implications: will FDA require a protocol amendment, additional monitoring, or interim safety reporting?
5. Tell me what to proactively communicate to FDA, whether a safety label update is likely at approval, and how to frame the safety profile for the NDA.

Call out where independent models are likely to disagree, and list follow-up documents a reviewer should request.

What to expect

• Adverse event clinical significance assessment
• Event type analysis (class vs. unexpected)
• Benefit-risk balance assessment
• FDA communication and protocol amendment recommendations
• Safety labeling implications for NDA

Review before you act

• Validate this output against source files before relying on it: Assess the clinical significance of the 3.2% vs. 1.4% adverse event rate: is this a drug-related effect, a chance finding, or an imbalance in baseline characteristics?.
• Validate this output against source files before relying on it: Review the adverse event types: are they class-related effects expected for this mechanism of action, or are they unexpected and potentially serious?.
• Validate this output against source files before relying on it: Assess the DSMB's decision to continue: is the benefit-risk balance supportable for the trial to continue to completion given the current signal?.
• Validate this output against source files before relying on it: Identify the regulatory implications: will FDA require a protocol amendment, additional monitoring, or interim safety reporting?.
• Confirm every cited figure, date, counterparty, or requirement against the attached originals — models compress and can drop a qualifier.
• Treat disagreement between models as a review item, especially on classification, materiality, and recommended next action.
• Do not authorize an operational, clinical, legal, credit, or enforcement action solely because the models agree.